GLP-1RAs have substantial potential for helping a wide range of
more severely afflicted (and more treatment-resistant/refractory) MCAS patients. Much more research is needed to clarify (1) which MCAS patients are the most appropriate candidates for GLP-1RA therapy and (2) optimal GLP-1RA drug and dose selection for various types of MCAS patients. #MastCell #MCAS #ThanksEhlersDanlos






